Bad Miss For Biocon’s Bevacizumab In US But Firm In 'Good Place'

Indian Company Remains Upbeat As It Reports Full-Year Results

 
• By Anju Ghangurde
  
Pandemic induced misses dull momentum for Biocon • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business